The aspirin resistance controversy: clinical entity or platelet heterogeneity?
Freedman
Jane E
JE
D001241:Aspirin / Q000494:pharmacology* / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control*; D051545:Cyclooxygenase 1 / Q000235:genetics / Q000502:physiology; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects* / Q000235:genetics; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D010979:Platelet Function Tests; D015995:Prevalence; D012008:Recurrence; D013928:Thromboxane A2 / Q000097:blood; D013997:Time Factors; D016312:Treatment Refusal
D010975:Platelet Aggregation Inhibitors; D013928:Thromboxane A2; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D001241:Aspirin